Your new post is loading...
Collaboration will harness French Atomic Energy Commission spin-out's IVI platform to develop lead candidates
|
Scooped by BigField GEG Tech |
Scoop.it!
No comment yet.
Sign up to comment
Pierre Fabre is partnering with immunotherapeutics startup H-Immune to generate anticancer antibody candidates using the latter’s proprietary In Vitro Immunization (IVI) technology. The collaboration will give Pierre Fabre access to the IVI platform for three different immune-oncology discovery programs. H-Immune will receive undisclosed R&D funding and potential future milestone payments.